[go: up one dir, main page]

FR2845385B1 - Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique - Google Patents

Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique

Info

Publication number
FR2845385B1
FR2845385B1 FR0212370A FR0212370A FR2845385B1 FR 2845385 B1 FR2845385 B1 FR 2845385B1 FR 0212370 A FR0212370 A FR 0212370A FR 0212370 A FR0212370 A FR 0212370A FR 2845385 B1 FR2845385 B1 FR 2845385B1
Authority
FR
France
Prior art keywords
thiohydantoin
therapeutics
compounds derived
derived
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0212370A
Other languages
English (en)
Other versions
FR2845385A1 (fr
Inventor
Benaissa Boubia
Khan Ou
Evelyne Chaput
Philippe Ratel
Jean Binet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Fournier SAS
Original Assignee
Laboratories Fournier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0212370A priority Critical patent/FR2845385B1/fr
Application filed by Laboratories Fournier SAS filed Critical Laboratories Fournier SAS
Priority to JP2004540883A priority patent/JP2006510600A/ja
Priority to PCT/FR2003/002904 priority patent/WO2004031160A2/fr
Priority to CA002500977A priority patent/CA2500977A1/fr
Priority to AU2003279442A priority patent/AU2003279442A1/en
Priority to EP03772390A priority patent/EP1546111A2/fr
Priority to US10/529,817 priority patent/US20060025589A1/en
Publication of FR2845385A1 publication Critical patent/FR2845385A1/fr
Application granted granted Critical
Publication of FR2845385B1 publication Critical patent/FR2845385B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0212370A 2002-10-01 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique Expired - Fee Related FR2845385B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0212370A FR2845385B1 (fr) 2002-10-04 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
PCT/FR2003/002904 WO2004031160A2 (fr) 2002-10-04 2003-10-03 Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete
CA002500977A CA2500977A1 (fr) 2002-10-04 2003-10-03 Composes derives de la 2-thiohydantoine et leur utilisation pour le traitement du diabete
AU2003279442A AU2003279442A1 (en) 2002-10-04 2003-10-03 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
JP2004540883A JP2006510600A (ja) 2002-10-04 2003-10-03 ２−チオヒダントインに由来する化合物及び治療におけるその使用
EP03772390A EP1546111A2 (fr) 2002-10-04 2003-10-03 Composes derives de la 2-thiohydantoine et leur utilisation pour le traitement du diabete
US10/529,817 US20060025589A1 (en) 2002-10-01 2003-10-03 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0212370A FR2845385B1 (fr) 2002-10-04 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique

Publications (2)

Publication Number Publication Date
FR2845385A1 FR2845385A1 (fr) 2004-04-09
FR2845385B1 true FR2845385B1 (fr) 2004-12-31

Family

ID=32011425

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0212370A Expired - Fee Related FR2845385B1 (fr) 2002-10-01 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique

Country Status (1)

Country Link
FR (1) FR2845385B1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
EP2368550B1 (fr) 2006-03-27 2013-09-04 The Regents of the University of California Modulateurs de récepteurs d'androgènes pour le traitement du cancer de la prostate et de maladies liées au récepteur de l'androgène
CN115737643A (zh) 2012-09-26 2023-03-07 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
AR102942A1 (es) 2014-12-11 2017-04-05 Bayer Cropscience Ag Derivados de arilsulfuro y arilsulfóxido de cinco miembros c-n-conectados, como plaguicidas
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE550650A (fr) * 1955-08-30
JPS5492962A (en) * 1977-12-01 1979-07-23 Wellcome Found Thiohydantoin compound
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
CA2238762A1 (fr) * 1995-11-28 1997-06-05 Sie-Yearl Chai Derives 2-thioxo-imidazolin-4-one et leur utilisation pour augmenter la cholesterolemie a lipoproteine de haute densite
EA200200311A1 (ru) * 1999-08-31 2002-08-29 Максиа Фармасьютикалз, Инк. Бензилиден-тиазолидиндионы и аналоги и их применение для лечения диабета

Also Published As

Publication number Publication date
FR2845385A1 (fr) 2004-04-09

Similar Documents

Publication Publication Date Title
FR21C1056I2 (fr) Composes de thienopyrimidine et utilisation
FR2823209B1 (fr) Nouvelles thiohydantoines et leur utilisation en therapeutique
MA28758B1 (fr) Composes d'aminoalkylglucosaminide phosphate et leur utilisation
EG23770A (en) Thin and dry diaper
EP1624935A4 (fr) Composites anti-adherence et methodes d'utilisation desdits composites
SI1499589T1 (sl) Derivati N-(fenil(piperidin-2-il)metil)benzamida,njihova priprava in njihova terapevtska uporaba
EP1608318A4 (fr) Antagonistes cxcr4 et leurs procedes d'utilisation
MA26348A1 (fr) 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine substituees et leur utilisation
AU2003261723A1 (en) Cxcr4 antagonist and use thereof
EP1831207A4 (fr) Composes d'aminopyrimidine et procedes d'utilisation correspondants
EP1589996A4 (fr) Preparation d'anticorps anti-integrine alpha beta 3 et utilisations associees
DE60305603D1 (de) Bankautomat
FR2845384B1 (fr) Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
EP1514679A4 (fr) Mat riau de film mince et proc d de pr paration associ
PT1513836E (pt) Derivados de piperazinilacilpiperidina, sua preparacao e sua aplicacao em terapeutica
EP1476150A4 (fr) Carboxyfullerenes et procedes d'utilisation de ceux-ci
EP1534353A4 (fr) Materiaux orthopediques derives de la keratine
FI20021149A0 (fi) Sondijärjestelmä, sondijärjestelmän vastaanotin sekä signaalinkäsittelymenetelmä sondivastaanottimessa
EP1633749A4 (fr) Composes de deazaflavine et leurs methodes d'utilisation
NO20031332D0 (no) Arylalkan-sulfonamider med endothelin-antagonistaktivitet
GB0308860D0 (en) Game system and game program
FR2845385B1 (fr) Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2833599B1 (fr) Polysaccharide amphotere, composition et utilisation
FR2838960B1 (fr) Composition comprenant des photochromes et son utilisation en cosmetique
EP1545287A4 (fr) Composes vasoregulateurs et procedes concernant leur utilisation

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20070629